Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
Glide Pharma secures further £2.2 million to accelerate development programme
October 29th, 2008
Specialty pharma company, Glide Pharma, announced it has raised a further £2.2 million to develop the Glide SDI™ - Solid Dose Injector. Despite the harsh economic climate, existing investors, led by the Oxford Technology VCTs, were quick to respond and were joined by a handful of new investors in a fully subscribed fundraising. The funding comes at an exciting stage in the company's development as it targets the biologics injectables market which is forecast to grow to over $50 billion by 2012. The Glide SDI is now in feasibility studies for delivering vaccines and biopharmaceuticals with five partners, three of which are new partners for 2008. Commenting on the...
Source: Vaccine Weekly (2008-10-29)
|
